image credit: Adobe Stock

FDA approves Gamida’s cell therapy for blood cancer patients

April 19, 2023


Omisirge is specifically indicated for individuals aged 12 years and older who are planned for umbilical cord blood transplantation following a myeloablative conditioning regimen, such as radiation or chemotherapy.

Stem cell transplantation is a common treatment for blood cancers, which represent about 10% of annual US cancer cases. One source of healthy stem cells is umbilical cord blood.

Before receiving this kind of transplant, patients will generally undergo a course of treatments to remove their own stem cells and prepare the body for new ones, which may weaken the immune system and increase the risk of severe infections.

Read More on PMLiVE